Healthcare
Ambu A/S(AMBBY)
Live Price
Offline$9.51
+0.00% today
1Y Change
-38.84%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $17.79B
- Revenue Growth
- +5.5%
- EPS Growth
- +144.3%
- Dividend Yield
- 0.6%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ambu A/S (AMBBY) is a Healthcare stock with a market cap of $17.79B and listed on OTC. The stock last traded around $9.51 and down 38.8% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +5.5%, EPS growth of +144.3%, a dividend yield of 0.6%. What stands out right now is revenue +5.5%, EPS +144.3%, free cash flow +21.2% with operating margin 11.6% and ROIC 8.7%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 32.9 and price/sales 2.9. Stock Foundry combines AMBBY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.5% vs +7.6% peer median
Operating Margin
Below sector median
+11.6% vs +19.4% peer median
P/E
Below sector median
32.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +5.5% and EPS at +144.3%, with operating margin around 11.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -6.3% | -8.2% | -4.6% |
2026 Feb 4, 2026 | โ | +0.0% | -6.4% | -16.9% |
2025 Nov 5, 2025 | โ | +0.0% | +3.2% | +8.2% |
Benchmark Edge
AMBBY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AMBBY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AMBBY Max Drawdown
-43.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AMBBY and SPY.
Company Overview
Ambu A/S
Other OTC
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, head immobilizers, CPR breathing barriers, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
- Leadership
- Britt Meelby Jensen
- IPO Date
- Jan 8, 2021
- Employees
- 5.0k
- Street Address
- Baltorpbakken 13
- Mailing
- Ballerup, 2750
- Region
- Ballerup, DK
- Reporting Currency
- USD
- Investor Line
- 45 72 25 20 00
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 32.9
- EV/EBITDA
- 16.6
- Price/Sales
- 2.9
- Price/Book
- 3.0
Growth
- Revenue
- +5.5%
- EPS
- +144.3%
- Free Cash Flow
- +21.2%
Profitability
- Gross Margin
- 55.9%
- Operating Margin
- 11.6%
- Net Margin
- 8.9%
- ROE
- 9.1%
- ROIC
- 8.7%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 2.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.